Fumi Kinose

1.2k total citations
26 papers, 857 citations indexed

About

Fumi Kinose is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Fumi Kinose has authored 26 papers receiving a total of 857 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Fumi Kinose's work include Lung Cancer Treatments and Mutations (8 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Cancer Mechanisms and Therapy (4 papers). Fumi Kinose is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Cancer Mechanisms and Therapy (4 papers). Fumi Kinose collaborates with scholars based in United States, Brazil and United Kingdom. Fumi Kinose's co-authors include Eric B. Haura, John M. Koomen, Uwe Rix, Bin Fang, Lily L. Remsing Rix, Yun Bai, Eric A. Welsh, Steven A. Eschrich, Brent M. Kuenzi and Jiannong Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Cancer Research.

In The Last Decade

Fumi Kinose

26 papers receiving 852 citations

Peers

Countries citing papers authored by Fumi Kinose

Since Specialization

Citations

This map shows the geographic impact of Fumi Kinose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumi Kinose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumi Kinose more than expected).

Fields of papers citing papers by Fumi Kinose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fumi Kinose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumi Kinose. The network helps show where Fumi Kinose may publish in the future.

Co-authorship network of co-authors of Fumi Kinose

This figure shows the co-authorship network connecting the top 25 collaborators of Fumi Kinose. A scholar is included among the top collaborators of Fumi Kinose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fumi Kinose. Fumi Kinose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis 2024 ·Cancer Research ·Xiaonan Xu, (unknown), (unknown), Kaizhen Wang, (unknown), (unknown), (unknown), Eric A. Welsh, Fumi Kinose, Uwe Rix, Florian A. Karreth	8
2	Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib 2023 ·ChemBioChem ·Qianqian Hu, (unknown), J. Cao, Bin Fang, (unknown), Fumi Kinose, Eric B. Haura, Harshani R. Lawrence, Robert C. Doebele, John M. Koomen, Uwe Rix	3
3	Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition 2021 ·Clinical Cancer Research ·Hitendra S. Solanki, Eric A. Welsh, Bin Fang, Victoria Izumi, Lancia Darville, (unknown), (unknown), Sandip Chavan, Fumi Kinose, (unknown), John M. Koomen, Uwe Rix, Eric B. Haura	64
4	Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling 2021 ·Molecular Pharmacology ·Laura Schubert, Anh T. Le, Adriana Estrada‐Bernal, Andrea E. Doak, Minjae Yoo, (unknown), (unknown), Fumi Kinose, Uwe Rix, Aik Choon Tan, Robert C. Doebele	6
5	CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines 2021 ·PLoS ONE ·Gabriëla Wright, (unknown), Bhaswati Sarcar, (unknown), Edna R. Gordián, Fumi Kinose, Natália J. Sumi, Uwe Rix, W. Douglas Cress	4
6	The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors 2021 ·Cell chemical biology ·Vinayak Palve, Claire E. Knezevic, Daniel S. Bejan, Yunting Luo, Xueli Li, (unknown), Eric A. Welsh, Bin Fang, Fumi Kinose, Eric B. Haura, Álvaro N.A. Monteiro, John M. Koomen, Michael S. Cohen, Harshani R. Lawrence, Uwe Rix	25
7	HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma 2019 ·Clinical Cancer Research ·Fernanda Faião‐Flores, Michael F. Emmons, Michael Durante, Fumi Kinose, Biswarup Saha, Bin Fang, John M. Koomen, Srikumar Chellappan, Silvya Stuchi Maria–Engler, Uwe Rix, Jonathan D. Licht, J. William Harbour, Keiran S.M. Smalley	69
8	Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia 2019 ·Scientific Reports ·Brent M. Kuenzi, Lily L. Remsing Rix, Fumi Kinose, Jodi L. Kroeger, Jeffrey E. Lancet, Eric Padron, Uwe Rix	21
9	Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets 2019 ·Cell chemical biology ·Natália J. Sumi, Claudia Ctortecka, Qianqian Hu, (unknown), Bin Fang, Lily L. Remsing Rix, Muhammad Ayaz, Fumi Kinose, Eric A. Welsh, Steven A. Eschrich, Harshani R. Lawrence, John M. Koomen, Eric B. Haura, Uwe Rix	13
10	Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells 2018 ·Molecular & Cellular Proteomics ·Claudia Ctortecka, Vinayak Palve, Brent M. Kuenzi, Bin Fang, Natália J. Sumi, Victoria Izumi, (unknown), Fumi Kinose, Lily L. Remsing Rix, Eric B. Haura, John M. Koomen, Uwe Rix	17
11	Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS -Wild-Type Melanoma Cell Lines 2017 ·Molecular Cancer Therapeutics ·Daniel Verduzco, Brent M. Kuenzi, Fumi Kinose, Vernon K. Sondak, Zeynep Eroglu, Uwe Rix, Keiran S.M. Smalley	13
12	Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer 2017 ·Scientific Reports ·Andrew Dhawan, Daniel Nichol, Fumi Kinose, Mohamed E. Abazeed, Andriy Marusyk, Eric B. Haura, Jacob G. Scott	57
13	Polypharmacology-based ceritinib repurposing using integrated functional proteomics 2017 ·Nature Chemical Biology ·Brent M. Kuenzi, Lily L. Remsing Rix, Paul A. Stewart, Bin Fang, Fumi Kinose, (unknown), Theresa A. Boyle, John M. Koomen, Eric B. Haura, Uwe Rix	61
14	PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer 2016 ·Molecular Cancer Therapeutics ·(unknown), Nicholas T. Woods, Gabriëla Wright, Lily L. Remsing Rix, Fumi Kinose, Jodi L. Kroeger, Elizabeth Remily-Wood, W. Douglas Cress, John M. Koomen, Stephen G. Brantley, Jhanelle E. Gray, Eric B. Haura, Uwe Rix, Álvaro N.A. Monteiro	21
15	Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling 2016 ·Molecular Cancer Therapeutics ·Jiannong Li, Bin Fang, Fumi Kinose, Yun Bai, Jae‐Young Kim, Y. Ann Chen, Uwe Rix, John M. Koomen, Eric B. Haura	18
16	Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS -Mutant Lung Cancer 2016 ·Molecular Cancer Research ·Jae‐Young Kim, Eric A. Welsh, Bin Fang, Yun Bai, Fumi Kinose, Steven A. Eschrich, John M. Koomen, Eric B. Haura	54
17	Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics 2016 ·Clinical Cancer Research ·Scott M. Haake, Jiannong Li, Yun Bai, Fumi Kinose, Bin Fang, Eric A. Welsh, Roy Zent, Jasreman Dhillon, Julio M. Pow‐Sang, Y. Ann Chen, John M. Koomen, W. Kimryn Rathmell, Mayer Fishman, Eric B. Haura	19
18	Abstract 675: Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia 2015 ·Cancer Research ·Brent M. Kuenzi, Lily L. Remsing Rix, Sateesh Kunigal, Fumi Kinose, Claire E. Knezevic, Gabriëla Wright, Jodi L. Kroeger, Jeffrey E. Lancet, Eric Padron, Uwe Rix	1
19	Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations 2014 ·Cancer Research ·Yun Bai, Jae‐Young Kim, (unknown), Bin Fang, Fumi Kinose, Lanxi Song, John M. Koomen, Jamie K. Teer, Kate Fisher, Y. Ann Chen, Uwe Rix, Eric B. Haura	34
20	Mass Spectrometry Mapping of Epidermal Growth Factor Receptor Phosphorylation Related to Oncogenic Mutations and Tyrosine Kinase Inhibitor Sensitivity 2010 ·Journal of Proteome Research ·Guolin Zhang, Bin Fang, (unknown), Hui‐Yi Lin, Fumi Kinose, Yun Bai, (unknown), Elizabeth Remily-Wood, Jiannong Li, Soner Altiok, Steven A. Eschrich, John M. Koomen, Eric B. Haura	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact